June 10 Product: Ipsen and Genfits Iqirvo Indication: Primary biliary cholangitis Monday, the FDA approved the first new drug in nearly a decade for primary biliary cholangitis: Ipsen and Genfits Iqirvo
Clinical trials of GLP-1 receptor agonists have shown average reductions in daily energy intake of roughly 2030% during early treatment phases , reflecting the combined effects of increased satiety and reduced food preoccupation
Retatrutide is Eli Lilly's Phase 3 experimental peptide that activates three metabolic receptorsGLP-1 (reduces appetite, slows digestion), GIP (improves insulin response), and glucagon (burns fat and calories)offering a new option for weight loss compared to predecessors like Semaglutide and Tirzepatide
doi: 10.1038/ncomms8629
Its primarily stored in your muscles, with smaller amounts in the liver and blood
If you suspect you may have injected into a blood vessel or feel unwell after an injection, seek medical advice promptly